Supplements and Compounds Library
Every article, presentation, spotlight, and news item we've tagged to Supplements and Compounds.
Showing 121–144 of 328
Sensory Stimulation Elevates Neuroprotective Lipid Proteins
Cognito's Spectris device, a non-invasive sensory stimulation wearable, increased cerebrospinal fluid levels of HDL-like lipid transport proteins in amyloid-positive mild cognitive impairment participants. This finding suggests sensory-driven neurostimulation may modulate lipid metabolism in ways that support cognitive resilience in early Alzheimer's disease.
New data show TrenibotE safety in repeat treatments
TrenibotE, an investigational neurotoxin, demonstrated consistent safety across repeat treatments with rapid onset at eight hours and duration of two to three weeks, with no neutralizing antibody development. Concurrent survey data indicate that over half of GLP-1–treated patients express concerns about facial appearance, with cost and fear of unnatural results as primary barriers to aesthetic intervention.
FDA clears Denali biologic as first brain-penetrating therapy
The FDA approved Avlayah, an enzyme replacement therapy that crosses the blood-brain barrier to treat neurologic manifestations of Hunter syndrome in children. The therapy achieved 91% reduction in cerebrospinal fluid heparan sulfate accumulation, addressing a progressive lysosomal storage disorder that damages neural tissue.
Dual-pathway obesity drug achieves dose escalation milestone
MetaVia's DA-1726 has advanced through dose escalation in Phase 1 trials, with all participants reaching target doses ranging from 32 mg to 64 mg. The drug represents a mechanistic shift in obesity treatment: rather than relying solely on appetite suppression, it combines hunger signaling with activation of energy expenditure pathways, potentially enabling weight loss with less severe dietary restriction.
Pfizer’s monthly obesity drug shows promise, spooks investors
Pfizer's PF-3944 demonstrated 11-12 percentage points greater weight loss than placebo in Phase 2b trials with monthly dosing, maintaining efficacy without plateau at 28 weeks. The drug's clinical promise is offset by higher discontinuation rates due to gastrointestinal side effects and direct comparison disadvantage relative to competitor therapies.
AstraZeneca signs $18.5b deal for next-gen slimming drugs
AstraZeneca's $18.5 billion licensing deal with CSPC Pharmaceutical Group targets next-generation obesity therapeutics, particularly SYH2082, designed for improved patient adherence and reduced cardiometabolic complications. Once-monthly dosing and AI-enabled peptide platforms position these agents as tools for sustained weight management and prevention of obesity-related disease burden.
Science Corp and Neurosoft unite to speed brain-computer care
A partnership between Science Corporation and Neurosoft Bioelectronics reduces brain-computer interface development costs from $75–100 million to under $5 million, accelerating clinical adoption of therapies for neurological conditions including epilepsy and tinnitus. For longevity practitioners, this infrastructure advancement enables faster restoration of neurological function and cognitive independence—essential dimensions of healthspan that outlive lifespan alone.
Aspen Neuroscience reports positive 12‑month ASPIRO results
Aspen Neuroscience's Phase 1/2a trial of sasineprocel (ANPD001), a cell-based therapy for Parkinson's disease, demonstrated safety and functional improvements at 12 months in eight patients, with gains in motor function, quality of life, and reduced medication burden. These results support advancement to Phase 3 evaluation of a regenerative approach to dopaminergic neurodegeneration.
BioAge Reports Positive Phase 1 Data for BGE-102
BGE-102, a novel NLRP3 inhibitor, achieved profound and sustained reductions in high-sensitivity C-reactive protein (hsCRP) and multiple inflammatory biomarkers in Phase 1 trials, with 87% of obese participants with elevated inflammation reaching normalized hsCRP levels (<2 mg/L) at the lower 60 mg daily dose. This positions the compound as a potential best-in-class anti-inflammatory therapeutic for cardiovascular and metabolic disease prevention.
FAD controls viral sensing and immune detection capacity
Flavin adenine dinucleotide (FAD), a fundamental metabolic cofactor, functions as an immune checkpoint molecule that regulates cGAS and RIG-I—two critical sensors of viral and cellular threat. This finding bridges metabolism and innate immunity, suggesting that metabolic state directly governs the body's capacity to detect and respond to infection and cellular danger.
Jupiter Neurosciences expands Nugevia addressable market with focus on GLP‑1 users
Jupiter Neurosciences is positioning its Nugevia supplement line to support individuals using GLP-1 weight-loss medications, targeting the physiological demands these drugs place on mitochondrial function, lean tissue preservation, and metabolic signaling. This represents a market expansion that acknowledges the need for targeted support during rapid metabolic change induced by pharmacological intervention.
Aspen wins official name for Parkinson’s cell therapy candidate
Aspen Neuroscience received WHO and AMA approval for the official name Sasineprocel for its autologous dopaminergic cell therapy derived from patient skin cells. The therapy aims to restore dopamine-producing neurons in Parkinson's disease without immunosuppression, currently in Phase 1/2a trials.
Alveus bags $197 million in booming obesity drug race
Alveus Therapeutics raised $197 million in Series A funding to advance next-generation obesity treatments, including ALV-100, which combines two metabolic signaling pathways to achieve durable weight loss, and ALV-200, an amylin receptor agonist representing a potential frontier beyond current GLP-1 approaches. This capital deployment reflects the biomedical sector's recognition of obesity as a chronic metabolic disease requiring mechanistically distinct therapeutic strategies.
Pretzel Therapeutics presents PX578 data supporting POLG disease treatment
PX578, a first-in-class small molecule activator of mitochondrial DNA polymerase gamma, demonstrated preclinical efficacy in restoring mitochondrial DNA levels and cellular energy production across multiple POLG disease models. The compound addresses the underlying genetic defect in mitochondrial DNA depletion syndromes, for which no disease-modifying treatments currently exist.
BioAge reports positive Phase 1 data for BGE-102
BGE-102, an oral NLRP3 inhibitor, demonstrated rapid and substantial reductions in high-sensitivity C-reactive protein (85–86% median reduction) and inflammatory markers in a Phase 1 trial, with 87–93% of treated participants normalizing hsCRP levels and no serious adverse events reported. This early evidence suggests a therapeutic approach to systemic inflammation that may have relevance to age-related disease prevention.
Anavex reports blarcamesine benefits in Parkinson’s disease model
Blarcamesine, a sigma-1 receptor agonist, demonstrated statistically significant improvements in motor function and reduced alpha-synuclein pathology in a preclinical Parkinson's disease model. The mechanism appears to engage underlying disease processes through modulation of cellular stress responses and protein homeostasis rather than symptomatic relief alone, with implications for disease-modifying approaches in neurodegeneration.
Vivtex inks $2.1b Novo Nordisk collab for oral obesity drug
Novo Nordisk's $2.1 billion partnership with Vivtex aims to convert injectable obesity and diabetes medications into oral formulations, addressing a critical gap between drug efficacy and real-world adherence. The collaboration targets peptide therapeutics that are difficult to deliver orally while maintaining bioavailability, signaling that the obesity treatment landscape is shifting from efficacy metrics toward practical administration and sustained patient compliance.
Wegovy gets cheaper – but at what cost to patients?
As GLP-1 drug prices fall through government programs and compounded alternatives, the FDA warns of safety risks in unapproved formulations—including dosing errors, improper storage, and hospitalizations. The accessibility gains must be weighed against supply chain integrity and long-term health outcomes that depend on consistent, verified dosing.
Multi-target ALS therapy targets inflammation and oxidative stress
NeuroSense has secured a South Korean patent for PrimeC, an oral combination therapy targeting neuroinflammation and oxidative stress in ALS, extending intellectual property protection through 2042. Phase 2b data demonstrated disease progression slowing and survival benefit, positioning the candidate for pivotal Phase 3 trials.
Cognito Therapeutics presents Spectris data in Alzheimer’s disease
Cognito Therapeutics presented clinical and biomarker data supporting Spectris, a non-invasive neurostimulation therapy using synchronized light and sound to modulate gamma frequency brain waves in Alzheimer's disease. Prior studies showed preserved brain structure, slowed cognitive decline, and reduced atrophy compared with controls, with favorable safety profiles and no amyloid-related imaging abnormalities.
Neuraly begins Phase 2 trial for progressive MS treatment
Neuraly has initiated a Phase 2 trial (TAG-MS) evaluating pegsebrenatide, a GLP-1 receptor agonist, in approximately 120 patients with progressive multiple sclerosis. The study measures brain volume changes and neurological markers over 96 weeks, building on preclinical evidence suggesting the drug modulates neuroinflammation and protects neural tissue.
Celularity secures $35m license deal to back longevity strategy
Celularity licensed its placental-derived biomaterials portfolio for up to $35 million in non-dilutive capital, allowing the company to redirect resources toward cell therapies targeting senescence, inflammation, and tissue degeneration. This repositioning reflects a strategic shift from broad biomaterials commercialization to targeted longevity interventions.
Breye Therapeutics reports strong early data for danegaptide in retinal disease
Danegaptide, an oral small molecule in Phase 1b trials, demonstrated tolerability and early clinical activity in 24 patients with diabetic retinopathy, showing reduced vascular leakage and macular edema over four weeks. The mechanism—stabilizing retinal vasculature against glucose-induced capillary breakdown—addresses a primary pathology in diabetic eye disease, with advancement to Phase 2 planned.
NeuroSense granted Brazilian patent for PrimeC composition
NeuroSense secured Brazilian patent protection for PrimeC, a fixed-dose combination of ciprofloxacin and celecoxib designed for neurodegenerative diseases including ALS and Alzheimer's. The patent, valid through 2042, follows U.S. and Australian approvals and supports ongoing Phase 3 development based on positive Phase 2b results.